The Perfect Storm: Diagnostic and Therapeutic Obstacles in Managing Hemophagocytic Lymphohistiocytosis in a HIV/AIDS Patient With Concurrent Miliary Tuberculosis and CMV Viremia

Abstract Introduction Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that infections, malignancies, and autoimmune disorders can trigger. Although rare, HIV, CMV, and tuberculosis (TB) have been identified as potential precipitants of HLH, and there remains a limited body of data to guide treatment strategies in such complex cases.Case Report A 34-year-old female with a recent diagnosis of HIV with AIDS on highly active antiretroviral therapy (HAART) started two months ago, and Esophageal candidiasis presented with chest pain, fever, chills, dysphagia, and myalgias. On examination, pleuritic chest pain and persistent oral candidiasis despite completion of fluconazole therapy were noted. Laboratory findings indicated anemia and a negative respiratory panel. Chest X-ray (CXR) and computed tomography (CT) imaging revealed diffuse multiple nodular infiltrates with upper lobe predominance consistent with Miliary TB. The patient's CD4 count was 27, and tests for Mycobacterium tuberculosis, including PCR, AFB smear, and culture, were positive without evidence of drug resistance. Bronchoalveolar lavage was negative for Pneumocystis jirovecii Pneumonia. Mycobacterium Avium Complex PCR was negative. Blood cultures showed no growth, but CMV DNA PCR was positive with high titers. She was continued on HAART as Immune Reconstitution Inflammatory Syndrome was ruled out, Micafungin for esophageal candidiasis, Ganciclovir for CMV Viremia, Bactrim for PCP prophylaxis, and quadruple therapy was initiated for miliary TB. Despite these interventions, her respiratory status progressively worsened, necessitating intubation and ICU admission. A follow-up CT chest revealed diffuse ground glass opacities, indicating acute respiratory distress syndrome with further respiratory decline. The patient's H-Score of 251 suggested a 99% probability of HLH. Hematology was consulted, and a bone marrow biopsy demonstrated hemophagocytosis with hypercellular marrow, reactive-appearing megakaryocytes, and mild plasmacytosis. The patient was started on pulse therapy steroid with Methylprednisone, one gram every day for 5 days. However, her condition continued to deteriorate, resulting in multiorgan failure and death. Discussion HLH is frequently fatal, with treatment involving immunosuppression through corticosteroids, chemotherapy, and hematopoietic cell transplantation. In patients with compromised immune function, such as those with HIV and concurrent opportunistic infections, managing HLH poses unique challenges, as Immunosuppressive therapy further exacerbates underlying infections and complicates clinical decisions and outcomes. Conclusion This case highlights the diagnostic and therapeutic complexities of HLH in HIV patients with concurrent TB and CMV. The high mortality rate associated with HLH in HIV patients (approximately 40%) underscores the importance of maintaining a high index of suspicion and implementing timely interventions to optimize patient outcomes.